Proteases
Proteases, also known as peptidases or proteolytic enzymes, consists of a large number of enzymes catalyzing the hydrolysis of peptide bonds and subsequently resulting in the degradation of protein substrates into amino acids. Proteases are involved in a wide range of human diseases, including cancer, neurodegenerative disorders, inflammatory diseases and cardiovascular diseases. Thus numerous proteases inhibitors (small molecules and proteins) have been identified to block activity of proteases. Proteases inhibitors can be classified into different types based on the class of proteases they inhibit through two general mechanisms, irreversible “trapping” reactions and reversible tight-binding reactions. Proteases inhibitors have been used as diagnostic or therapeutic agents for the treatment of proteases-related diseases.
- B4950 Darunavir EthanolateSummary: nonpeptidic HIV protease inhibitor
- C5818 MMP-2 Inhibitor IISummary: irreversible inhibitor of MMP-2
- C5830 PD 145305Summary: selective inhibitor of calpains
- A1902 Z-VAD-FMK102 CitationTarget: CaspasesSummary: Cell-permeable, irreversible pan-caspase inhibitor
- B5153 Y-29794 oxalateSummary: Inhibitor of prolyl endopeptidase
- B5415 PF 429242Summary: inhibitor of sterol regulatory element-binding protein (SREBP) site 1 protease
- B5657 MKT 077Summary: mortalin-2 (mot-2) inhibitor
- B5780 UAMC 00039 dihydrochlorideTarget: Dipeptidyl-peptidase IISummary: dipeptidyl peptidase II (DPP-II) inhibitor
- B7393 GeduninTarget: HSP90Summary: naturally occurring Hsp90 inhibitor
- A1038 Amyloid β-Peptide (10-20) (human)Summary: Initiates neurodegeneration in Alzheimer disease